Disease characteristics at randomization
| . | IL-2, no. (%), n = 99 . | Observation, no. (%), n = 95 . |
|---|---|---|
| Histology | ||
| Low | 16 (16) | 13 (14) |
| Intermediate/high | 83 (84) | 82 (86) |
| Induction and salvage therapy response | ||
| Induction therapy CR or PR followed by relapse, then CR or PR to salvage therapy (sensitive) | 77 (78) | 76 (80) |
| Induction therapy CR or PR followed by relapse, but no response to salvage therapy (resistant) | 12 (12) | 9 (9) |
| No response to induction therapy (resistant) | 10 (10) | 10 (11) |
| Performance status | ||
| 0 or 1 | 95 (96) | 87 (92) |
| 2 | 4 (4) | 8 (8) |
| . | IL-2, no. (%), n = 99 . | Observation, no. (%), n = 95 . |
|---|---|---|
| Histology | ||
| Low | 16 (16) | 13 (14) |
| Intermediate/high | 83 (84) | 82 (86) |
| Induction and salvage therapy response | ||
| Induction therapy CR or PR followed by relapse, then CR or PR to salvage therapy (sensitive) | 77 (78) | 76 (80) |
| Induction therapy CR or PR followed by relapse, but no response to salvage therapy (resistant) | 12 (12) | 9 (9) |
| No response to induction therapy (resistant) | 10 (10) | 10 (11) |
| Performance status | ||
| 0 or 1 | 95 (96) | 87 (92) |
| 2 | 4 (4) | 8 (8) |